A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*-Reference-Cited by-同舟云学术

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*

Published:2020-07-13 Issue:2 Volume:184 Page:270-280
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Elewski B.¹^ORCID,Brand S.²³^ORCID,Degenhardt T.²³,Curelop S.²³,Pollak R.⁴,Schotzinger R.²⁵,Tavakkol A.²⁶,Alonso‐Llamazares Javier,Ashton Scott J.,Bhatia Neal,Billings Michael,Blauvelt Andrew,Bystol Norman,Dodson Brandt,Gold Michael H.,Grande Kimberly,Jarratt Michael,Jones Terry S.,Kasper Maria A.,Kempers Steven E.,McConnehey Brock,Noss Michael,Pariser David,Parish Lawrence,Rich Phoebe,Ahmad Samady Joseph,Schlessinger Joel,Schumacher Doug,Stein Kenneth,Strout Cynthia,Tschen Eduardo,Tu John H.,Weisfeld Max

Affiliation:

1. Department of Dermatology University of Alabama at Birmingham Birmingham AL USA

2. Viamet Pharmaceuticals Inc. Durham NC USA

3. Mycovia Pharmaceuticals Durham NC USA

4. Endeavor Clinical Trials San Antonio TX USA

5. Selenity Therapeutics Durham NC USA

6. Moberg Pharma Stockholm Sweden

Publisher

Wiley

Subject

Dermatology

Link